HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Pharma

Takeda Pharmaceutical Company Limited

1
Articles
Mentioned
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
0.95
Relevance Score

Coverage Timeline

April 2026
Apr 11, 2026
Take it in context. Takeda’s $4 billion for orexin agonists, GSK’s $2 billion-plus for sleep-wake disorder assets, big sums, all structured with heavy milestone components.
Related Companies